Patents by Inventor Susanne M. Gollin

Susanne M. Gollin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Patent number: 9080216
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: July 14, 2015
    Assignee: University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/Chek1 as prognostic indicators in cancer
    Patent number: 8877728
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: November 4, 2014
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Patent number: 8722325
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: May 13, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • GENETIC CHANGES IN ATM AND ATR/CHEK1 AS PROGNOSTIC INDICATORS IN CANCER
    Publication number: 20140088169
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 27, 2014
    Applicant: University of Pittsburgh - of the CommonWealth System of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Hijang
  • Genetic Changes In ATM And ATR/Chek1 As Prognostic Indicators In Cancer
    Publication number: 20130338212
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 19, 2013
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Patent number: 8466123
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: June 18, 2013
    Assignee: Univeristy of Pittsburgh—of The Commonwealth System of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • GENETIC CHANGES IN ATM AND ATR/CHEK1 AS PROGNOSTIC INDICATORS IN CANCER
    Publication number: 20120295951
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 22, 2012
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Patent number: 8263329
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: September 11, 2012
    Assignee: University of Pittsburgh - Of The Commonwealth System Of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • GENETIC CHANGES IN ATM AND ATR/CHEK1 AS PROGNOSTIC INDICATORS IN CANCER
    Publication number: 20120220645
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 30, 2012
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Patent number: 8173366
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: May 8, 2012
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Publication number: 20100324112
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Application
    Filed: March 28, 2008
    Publication date: December 23, 2010
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
  • Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
    Publication number: 20100173971
    Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
    Type: Application
    Filed: September 15, 2009
    Publication date: July 8, 2010
    Inventors: Susanne M. Gollin, Rahul Atul Parikh, Xin Huang